How does #ESMOMCBS v2.0 reflect the evolving #oncology treatment landscape and the priorities of #PatientsWithCancer? Sjoukje Oosting shares her insights in the #ESMODailyReporter. 🔗 ow.ly/8aJt50WBROf

#ESMOTATAsia25: Presentations highlight the value of integrating #PatientReportedOutcomes (#PRO) into #EarlyPhaseTrials with guidance on standardisation. Read more in the #ESMODailyReporter 🔗 dailyreporter.esmo.org/esmo-targete...

#ESMOTATAsia25: In an Opinion piece in the #ESMODailyReporter, Lillian Siu discusses the growth of early #oncology #ClinicalTrials in #AsiaPacific but highlights the need for improved trial access in low- and middle-income countries. 🔗 dailyreporter.esmo.org/esmo-targete...

#ESMOTATAsia25: Exploratory #omics and #MachineLearning revealed an 11-gene signature associated with response after #chemoradiotherapy for #CervicalCancer. MMP2 was identified as a key target. Read more in the #ESMODailyReporter 🔗 buff.ly/cHluzz7

Such a pleasure to work with this team!! #ESMO25 is just a few months ahead!

Thank you @myesmo.bsky.social #ESMOGI2025 chairs & organizing committee to bring GI #rarecancers to the stage and having me in good company. I hope I brought some awareness to #appendixcancers #pseudomyxoma #peritonealmesothelioma #ESMOAmbassadors @acpmpresearch.bsky.social

Interesting mini-Oral presentation from Dr Francesca Negri about the assessment of tumour immune microenvironment as a prognostic marker in Locally Advanced Rectal Cancer using a cohort from STAR-01 #ESMOGI25 @myesmo.bsky.social #ESMOAmbassadors

Impressive review of the use of blood based assays for screening in Colorectal Cancer at #ESMOGI25 by Prof Sinicrope Take a closer look at the takeaway points!! @myesmo.bsky.social #ESMOAmbassadors

AI revolution coming to #ESMOGI25 Very interesting presentations from Prof Magali Svrcek and @jnkt.bsky.social about the use and potential of #ArtificialIntelligence @myesmo.bsky.social #ESMOAmbassadors

Amazing trip through translational research in colorectal cancer from Sanger sequencing to Single Cell by Prof. Federica de Nicolantonio at @myesmo.bsky.social #ESMOGI25 #ESMOAmbassadors

Starting the 2nd day at @myesmo.bsky.social #ESMOGI25 with a Multidisciplinary Tumour Board in Rectal Cancer! #ESMOAmbassadors

This is really very clever science!!! www.cell.com/cancer-cell/...

ESMO-MCBS v2.0 is now out. Significant enhancements in cancer therapies evaluation: > robust 🔍 understanding of score’s meaning, ➕ accuracy, fairness, utility of treatment assessments, 🪞 advances in science, clinical practice, patient input.

As the #oncology field evolves, ESMO is keeping pace - regularly ensuring its tools reflect the latest in #ClinicalEvidence and regulatory shifts. An important evolution is just around the corner — keep an eye out. #ESMOMCBS

The Manchester Colorectal and Peritoneal Oncology Centre (CPOC) experience in colorectal peritoneal metastasis management is out in press! More clinical trials are needed in this space after PRODIGE-7! www.clinical-colorectal-cancer.com/article/S153...

Fresh start @bsky.app Hopefully I will reconnect here with known colleagues and new ones in the fields of #gastrointestinalcancers #rarecancers #appendixtumours #pseudomyxomaperitonei #translationalresearch and #drugdevelopment Espero volver a conectar con viejos conocidos y encontrar gente nueva